Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.